Vilobelimab

• Description:

  Vilobelimab (CaCP-29, IFX-1), a monoclonal antibody targeting C5a, inhibits this pro-inflammatory complement component, which is pivotal in causing organ dysfunction. By preventing the activation and chemotaxis of neutrophils and reducing inflammatory signaling, Vilobelimab could benefit researching conditions such as sepsis and COVID-19 .

• Stability:

  ≥ 2 years

• Purity:

  >98% (HPLC)

• Molecular Formula:

  ——

• Notes:

  Research use only, not for human use.

• Receptor:

  Others

• CAS Number:

  2250440-41-4